ArticleScience translational medicine2024
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Targeting DNA damage response to enhance cancer immunotherapy efficacy: molecular mechanisms and clinical advances.Medical oncology (Northwood, London, England) · 2025Pooled it
- BKJournal of neuro-oncology · 2026Article
- Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment.International journal of molecular sciences · 2026Review
- SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.iScience · 2026Article
- Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma.International journal of radiation oncology, biology, physics · 2026Review
- Divergent Roles of Canonical and Non-Canonical Mismatch Repair in Regulating Temozolomide Sensitivity in Glioblastoma.International journal of molecular sciences · 2026Review
- DNA-PKcs inhibition sensitizes glioblastoma to radiotherapy through reprogramming of tumor cell states and immune microenvironment cell types.Research square · 2026Article
- The Size of Glioblastoma Spheroids Influences Patterns of Invasion and Temozolomide Efficacy.Tissue engineering. Part C, Methods · 2026Article
- ISGylation of γH2AX retains MDC1 and facilitates homologous recombination repair causing radioresistance in esophageal adenocarcinoma.The Journal of biological chemistry · 2026Article
- Radiotherapy enhances M1 macrophage immunogenic activity through IFNs induction and stimulation in TP53-wild type tumors.Cancer immunology, immunotherapy : CII · 2026Article
- Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine glioma.Communications biology · 2026Article
- Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities.Frontiers in oncology · 2026Review
- Inhibition of ATM, ATR and DNA-PK radiosensitises 3D uveal melanoma models to X-rays and proton beam therapy.Frontiers in oncology · 2026Article
- Glutamine metabolism and its roles in tumor radiotherapy by regulating DNA damage repair.Frontiers in cell and developmental biology · 2026Review
- STING signaling pathway: An oasis in the glioblastoma immune desert.Theranostics · 2026Review
- Article
- BRD4 inhibition sensitizes glioblastoma to radiotherapy by suppressing super-enhancer-driven COL1A1.Oncogene · 2025Article
- Review
- The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts.Neuro-oncology · 2025Article
- Differential Clearance of [medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Jiajia ChenDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0000-8413-5970
Daniel J LavertyDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0003-4529-2302
Surabhi TaleleDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55905, USA.
Ashwin BaleDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.ORCID 0000-0001-7938-1632
Brett L CarlsonDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2460-3079
Kendra A PorathDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0009-0248-0523
Katrina K BakkenDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0009-0009-8900-0077
Danielle M BurgenskeDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-0014-5579
Paul A DeckerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-3756-4227
Rachael A VaubelDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-8842-5975
Jeanette E Eckel-PassowDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-6113-1114
Rohit BhargavaDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.ORCID 0000-0001-7360-994X
Zhenkun LouDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-1938-3091
Petra HamerlikAstraZeneca, Cambridge, UK.
Brendan HarleyDepartment of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.ORCID 0000-0001-5458-154X
William F ElmquistDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55905, USA.
Zachary D NagelDepartment of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0003-2104-2093
Shiv K GuptaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-9107-9935
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7489-4885
Mayo Clinic · USUniversity of Illinois Urbana-Champaign · USHarvard University · USMayo Clinic in Florida · USUniversity of Minnesota · USAstraZeneca (United Kingdom) · GB
Funding
Training Program in Molecular and Integrative Physiological SciencesT32HL007118 · NHLBI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LU, QUAN · 1985 to 2025
$14.3MThe Center for Label-free Imagingand Multiscale Biophotonics (CLIMB)P41EB031772 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Stephen A Boppart · 2022 to 2026
$7.6MTherapy Evaluation CoreU19CA264362 · NCI · MAYO CLINIC ROCHESTER · PI PARNEY, IAN F · 2021 to 2025
$7.6MSynthetic manipulation of engineered perivascular nichesR01CA256481 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HARLEY, BRENDAN A. · 2021 to 2025
$3.4MTargeting Defective DNA Damage Response Pathways in IDH1/2-mutant AMLR01CA266604 · NCI · YALE UNIVERSITY · PI Ranjit Bindra, Stephanie Halene · 2022 to 2026
$3.3MPre-Clinical Novel Radiosensitizer Evaluation Program for Brain TumorsU01CA227954 · NCI · MAYO CLINIC ROCHESTER · PI SARKARIA, JANN N. · 2018 to 2022
$3.0MSensitizing Ovarian Cancer To PARP inhibitor and platinum treatmentR01CA264600 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2021 to 2025
$1.8MRole of mismatch repair in regulating effects of PARP inhibition in GlioblastomaR03CA201612 · NCI · MAYO CLINIC ROCHESTER · PI GUPTA, SHIV KUMAR · 2017 to 2018
$159kNCI NIH HHS R01 CA256481NCI NIH HHS R01 CA264600NCI NIH HHS R01 CA266604NCI NIH HHS R03 CA201612NCI NIH HHS U01 CA227954NCI NIH HHS U19 CA264362NHLBI NIH HHS T32 HL007118NIBIB NIH HHS P41 EB031772
Abstract
ATM is a key mediator of radiation response, and pharmacological inhibition of ATM is a rational strategy to radiosensitize tumors. AZD1390 is a brain-penetrant ATM inhibitor and a potent radiosensitizer. This study evaluated the spectrum of radiosensitizing effects and the impact of
Indexed as
GlioblastomaPyridinesQuinolonesTumor Suppressor Protein p53Ataxia Telangiectasia Mutated ProteinsDNA RepairHumansSignal TransductionAtaxia Telangiectasia Mutated ProteinsATM protein, humanAZD1390PyridinesQuinolonesTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.